SEC Form 4 · accession 0001140361-16-089146
Corvus Pharmaceuticals, Inc. · CRVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Leiv Lea
Officer — Chief Financial Officer
Period of report
Dec 7, 2016
Accepted (ET)
Dec 8, 2016 · 7:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001626971
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $16.37 | Dec 7, 2016 | A | 25,000 | A | — | Dec 7, 2026 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The underlying shares subject to the option vest and become exercisable as to one-forty-eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from December 7, 2016, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.